NO327425B1 - Vannopploselige fenylpyridazinderivater medisiner inneholdende disse, samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom - Google Patents

Vannopploselige fenylpyridazinderivater medisiner inneholdende disse, samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom Download PDF

Info

Publication number
NO327425B1
NO327425B1 NO20041250A NO20041250A NO327425B1 NO 327425 B1 NO327425 B1 NO 327425B1 NO 20041250 A NO20041250 A NO 20041250A NO 20041250 A NO20041250 A NO 20041250A NO 327425 B1 NO327425 B1 NO 327425B1
Authority
NO
Norway
Prior art keywords
pyridazin
fluoro
methyl
isobutyl
methoxyphenyl
Prior art date
Application number
NO20041250A
Other languages
English (en)
Norwegian (no)
Other versions
NO20041250L (no
Inventor
Hiromichi Shigyo
Seiichi Sato
Yoshinori Kyotani
Tomoyuki Koshi
Takahiro Kitamura
Hideo Yoshizaki
Kyoko Yasuoka
Shunji Takemura
Junko Totsuka
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of NO20041250L publication Critical patent/NO20041250L/no
Publication of NO327425B1 publication Critical patent/NO327425B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20041250A 2001-09-26 2004-03-25 Vannopploselige fenylpyridazinderivater medisiner inneholdende disse, samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom NO327425B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32456901P 2001-09-26 2001-09-26
PCT/JP2002/009863 WO2003027077A1 (fr) 2001-09-26 2002-09-25 Derives de phenylpyridazine solubles dans l'eau et medicaments contenant ceux-ci

Publications (2)

Publication Number Publication Date
NO20041250L NO20041250L (no) 2004-03-25
NO327425B1 true NO327425B1 (no) 2009-06-29

Family

ID=23264178

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041250A NO327425B1 (no) 2001-09-26 2004-03-25 Vannopploselige fenylpyridazinderivater medisiner inneholdende disse, samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom

Country Status (17)

Country Link
US (2) US6869954B2 (ja)
EP (1) EP1431293B1 (ja)
JP (1) JP4280165B2 (ja)
KR (1) KR20040039377A (ja)
CN (1) CN1304379C (ja)
AT (1) ATE512139T1 (ja)
AU (1) AU2002332286B2 (ja)
BR (1) BR0212848A (ja)
CA (1) CA2461806A1 (ja)
HK (1) HK1070068A1 (ja)
HU (1) HUP0402149A3 (ja)
MX (1) MXPA04002939A (ja)
NO (1) NO327425B1 (ja)
NZ (1) NZ531982A (ja)
PL (1) PL368340A1 (ja)
RU (1) RU2302413C2 (ja)
WO (1) WO2003027077A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078751A1 (ja) * 2003-03-07 2004-09-16 Kowa Co., Ltd. ベンゾフラン誘導体
KR20050113627A (ko) * 2003-03-18 2005-12-02 코와 가부시키가이샤 수용성 페닐피리다진 유도체 및 이를 함유하는 의약
WO2021124346A1 (en) * 2019-12-18 2021-06-24 Abida / Novel 4-(6-oxo-3-substituted phenylpyridazin-1(6 h)-yl)benzaldehydes of pharmaceutical interest

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404203A (en) * 1981-05-14 1983-09-13 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
DE4134467A1 (de) * 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
ES2324126T3 (es) 1997-11-19 2009-07-30 Kowa Co., Ltd. Derivados de piridazina y medicamentos que los contienen como ingrediente activo.
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
EP1319659B1 (en) * 2000-09-18 2009-03-11 Eisai R&D Management Co., Ltd. Triazinones and medicinal use thereof
US6861428B2 (en) 2001-09-26 2005-03-01 Kowa Co., Ltd. Water-soluble phenylpyridazine compounds and compositions containing the same

Also Published As

Publication number Publication date
CN1304379C (zh) 2007-03-14
HK1070068A1 (en) 2005-06-10
HUP0402149A2 (hu) 2005-02-28
RU2004112532A (ru) 2005-03-27
RU2302413C2 (ru) 2007-07-10
ATE512139T1 (de) 2011-06-15
PL368340A1 (en) 2005-03-21
EP1431293B1 (en) 2011-06-08
KR20040039377A (ko) 2004-05-10
WO2003027077A1 (fr) 2003-04-03
US20050085480A1 (en) 2005-04-21
HUP0402149A3 (en) 2005-08-29
AU2002332286B2 (en) 2007-10-18
JP4280165B2 (ja) 2009-06-17
NO20041250L (no) 2004-03-25
US20030119838A1 (en) 2003-06-26
EP1431293A1 (en) 2004-06-23
CA2461806A1 (en) 2003-04-03
CN1558903A (zh) 2004-12-29
US7087606B2 (en) 2006-08-08
JPWO2003027077A1 (ja) 2005-01-06
BR0212848A (pt) 2004-08-17
MXPA04002939A (es) 2004-06-18
NZ531982A (en) 2005-08-26
US6869954B2 (en) 2005-03-22
EP1431293A4 (en) 2004-12-22

Similar Documents

Publication Publication Date Title
TW502025B (en) Pyridazine derivatives having inhibitory activity against interleukin-1β production and pharmaceutical composition containing the same
US7501410B2 (en) Methods of inhibiting BTK and SYK protein kinases
TWI287545B (en) New pyridazin-3(2h)-one derivatives
EP0482208B1 (en) Pyridazinone derivative
RU2490265C2 (ru) Пиридазиноновые производные в качестве ингибиторов parp
WO2009123986A1 (en) Apoptosis signal-regulating kinase 1 inhibitors
RU2269519C2 (ru) Соединения фенилпиридазина и содержащие их лекарственные средства
CN101918395B (zh) 三唑联噁二唑衍生物
JP2002518377A (ja) アリールアルカノイルピリダジン
EP4055016A1 (en) Gpr52 modulator compounds
US20060142292A1 (en) Water-soluble phenylpyridazine derivative and medicine containing the same
JP4280165B2 (ja) 水溶性フェニルピリダジン誘導体及びこれを含有する医薬
US6861428B2 (en) Water-soluble phenylpyridazine compounds and compositions containing the same
CN112543757A (zh) 对结核菌具有抗菌活性的缩合氮杂杂芳基化合物
KR100911069B1 (ko) 치환된 알킬아미노피리다지논 유도체, 이의 제조 방법 및이를 함유하는 약제학적 조성물
JP2006504803A (ja) ピラゾール誘導体
HU227255B1 (en) Novel piperidine-alkyl-amino-pyridazine derivatives, pharmaceutical compositions containing the same and process for the preparation of the active ingredient
MXPA05005137A (es) Alquil-piridazinonas sustituidas para el tratamiento de trastornos de la memoria y del aprendizaje.
MXPA00008549A (en) Novel pyridazine derivatives and drugs containing the same as the active ingredient

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees